Table 2 Univariable analyses of overall survival and progression-free survival in patients with available pre-treatment C-reactive protein-to-albumin ratio data.

From: High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma

 

OS

PFS

HR

(95% CI)

p

HR

(95% CI)

p

Age > 60 years

2.81

(1.09–7.27)

0.033

2.06

(1.05–4.03)

0.035

Stage (III, IV)

5.66

(1.66–19.23)

0.006

4.51

(1.98–10.25)

 < 0.001

LDH > UNL

6.77

(1.57–29.14)

0.010

3.19

(1.40–7.25)

0.006

ECOG PS > 1

4.14

(1.67–10.29)

0.002

3.49

(1.69–7.21)

0.001

EN > 1

2.31

(0.98–5.45)

0.055

1.85

(0.97–3.51)

0.061

CAR > 0.158

11.22

(2.61–48.28)

0.001

5.68

(2.50–12.93)

 < 0.001

Cycles of R-CHOP > 6a

2.14

(0.72–6.38)

0.173

1.97

(1.03–3.76)

0.040

Non-GCB typeb

3.26

(0.76–13.91)

0.110

1.90

(0.85–4.23)

0.118

  1. OS overall survival, PFS progression-free survival, HR hazard ratio, CI confidence interval, LDH lactate dehydrogenase, UNL upper normal limit, ECOG PS Eastern Cooperative Oncology Group performance status, EN extranodal, CAR C-reactive protein-to-albumin ratio, GCB germinal centre B-cell.
  2. aCompared to 6.
  3. bCompared to GCB type.
Back to article page